uniQure (NASDAQ:QURE) Share Price Crosses Above 50 Day Moving Average - What's Next?

Key Points

• uniQure N.V. (NASDAQ:QURE) shares have recently crossed above their 50-day moving average of $14.91, trading as high as $15.48 before closing at $15.21.
• Despite an upgrade from some analysts, the stock currently holds a Moderate Buy rating with an average target price of $37.82, alongside recent downgrades from certain firms.
• Insider trading activity has been noted, with directors selling shares and a total of 22,144 shares sold by insiders over the past 90 days.

uniQure N.V. (NASDAQ:QURE - Get Free Report) passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $14.91 and traded as high as $15.48. uniQure shares last traded at $15.21, with a volume of 824,768 shares traded.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Chardan Capital reiterated a "buy" rating and issued a $38.00 target price on shares of uniQure in a report on Friday, May 30th. HC Wainwright restated a "buy" rating and set a $70.00 price target on shares of uniQure in a report on Thursday, May 29th. Cantor Fitzgerald upgraded shares of uniQure to a "strong-buy" rating in a report on Monday, May 19th. Guggenheim restated a "buy" rating and set a $28.00 price target on shares of uniQure in a report on Monday, May 12th. Finally, Wall Street Zen lowered shares of uniQure from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $37.82.

uniQure Price Performance

The stock's 50-day moving average is $14.94 and its 200 day moving average is $13.68. The stock has a market capitalization of $687.05 million, a PE ratio of -2.86 and a beta of 0.08. The company has a quick ratio of 11.99, a current ratio of 11.99 and a debt-to-equity ratio of 1.53.

uniQure (NASDAQ:QURE - Get Free Report) last posted its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.20. uniQure had a negative net margin of 1,077.05% and a negative return on equity of 483.87%. As a group, equities analysts predict that uniQure N.V. will post -3.75 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Madhavan Balachandran sold 2,112 shares of the company's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $30,518.40. Following the completion of the sale, the director directly owned 37,697 shares of the company's stock, valued at approximately $544,721.65. This represents a 5.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David D. Meek sold 2,112 shares of the company's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $30,518.40. Following the sale, the director directly owned 34,190 shares of the company's stock, valued at approximately $494,045.50. This represents a 5.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 22,144 shares of company stock valued at $322,426. 4.79% of the stock is owned by company insiders.

Institutional Trading of uniQure

Several large investors have recently modified their holdings of the company. Tudor Investment Corp ET AL raised its stake in uniQure by 5.9% during the 4th quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company's stock valued at $438,000 after purchasing an additional 1,371 shares during the last quarter. Wells Fargo & Company MN raised its stake in uniQure by 13.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after purchasing an additional 1,503 shares during the last quarter. Northern Trust Corp raised its stake in uniQure by 2.1% during the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock valued at $1,688,000 after purchasing an additional 1,923 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in uniQure by 6.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company's stock valued at $1,253,000 after purchasing an additional 3,996 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in uniQure during the 2nd quarter valued at $117,000. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.